Bris­tol My­ers bets $100M on Avid­i­ty's RNA ther­a­pies for car­dio­vas­cu­lar dis­eases

Bris­tol My­ers Squibb is fur­ther tap­ping in­to Avid­i­ty Bio­sciences for $100 mil­lion up­front to work on up to five car­dio­vas­cu­lar tar­gets.

The Big Phar­ma wants …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER